Chemical delivery systems and soft drugs: Retrometabolic approaches of drug design
Open Access
- 1 September 2014
- journal article
- review article
- Published by Springer Nature in Saudi Pharmaceutical Journal
- Vol. 22 (4) , 290-302
Abstract
Inclusion of metabolic considerations in the drug design process leads to significant development in the field of chemical drug targeting and the design of safer drugs during past few years which is a part of an approach now designated as Retro metabolic drug design (RMDD). This approach represents systematic methodologies that integrate structure-activity and structure-metabolism relationships and are aimed to design safe, locally active compounds with an improved therapeutic index. It embraces two distinct methods, chemical delivery systems and a soft drug approach. Present review recapitulates an impression of RMDD giving reflections on the chemical delivery system and the soft drug approach and provides a variety of examples to embody its concepts. Successful application of such design principles has already been applied to a number of marketed drugs like esmolol; loteprednol etc., and many other candidates like beta blockers, ACE inhibitors, alkylating agents, antimicrobials etc., are also under investigation.Keywords
This publication has 43 references indexed in Scilit:
- Ophthalmic drug design based on the metabolic activity of the eye: Soft drugs and chemical delivery systemsThe AAPS Journal, 2005
- Synthesis and Biological Evaluation of Novel Cyclosporin A Analogues: Potential Soft Drugs for the Treatment of Autoimmune DiseasesJournal of Medicinal Chemistry, 2003
- Strategies To Target Kyotorphin Analogues to the BrainJournal of Medicinal Chemistry, 1998
- l-Carnitine Esters as “Soft”, Broad-Spectrum Antimicrobial AmphiphilesJournal of Medicinal Chemistry, 1998
- Design of Biologically Safer Chemicals Based on Retrometabolic Concepts1996
- Brain-Targeted Delivery of a Leucine-enkephalin Analogue by Retrometabolic DesignJournal of Medicinal Chemistry, 1996
- (R)-2-(3-mercapto-2(S)-methyl-1-oxopropoxy)-3-(methylthio)propanoic acid (FPL 66564), the first ultra-short-acting angiotensin converting enzyme inhibitorJournal of Medicinal Chemistry, 1992
- Ester derivatives of 2,6-bis(1-pyrrolidinylmethyl)-4-benzamidophenol as short-acting antiarrhythmic agents. 1Journal of Medicinal Chemistry, 1989
- Effects of Induction of Cytochrome P-450 Enzymes on the Concentration of Foreign Compounds and Their Metabolites and on the Toxicological Effects of These CompoundsDrug Metabolism Reviews, 1979
- Chemical Aspects of Selective ToxicityNature, 1958